Completed PHASE2 INTERVENTIONAL 1-arm NCT00947453

Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast

The Effect of Montelukast Therapy on mRNA Profile of Matrix Metalloproteinases and Their Inhibitors in the Sputum of Patients With Asthma

Sponsor: Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

Conditions Asthma

Interventions montelukast

Updated 5 times since 2017 Last updated: Aug 22, 2012 Started: Jul 31, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00947453, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK), it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
University of East Anglia

Data source: University of East Anglia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norwich, United Kingdom